OBJECTIVE: To estimate whether women aged 20-32 years who fulfilled National Institutes of Health criteria for polycystic ovary syndrome (PCOS) would be at higher risk for subsequent development of incident diabetes, dyslipidemia, and hypertension, and to estimate whether normal-weight women with PCOS would have the same degree of cardiovascular risk as overweight women with PCOS. METHODS: We estimated the association of PCOS with incident diabetes, dyslipidemia, and hypertension over a period of 18 years among 1,127 white and African-American women in the Coronary Artery Risk Development in Young Adults cohort. We classified women at baseline (ages 20-32 years) based on self-reported symptoms and serum androgen measures using National Institutes of Health PCOS criteria. We estimated the association of PCOS and subsequent cardiovascular risk factors, independent of baseline body mass index (BMI), using multivariable logistic regression. Additionally, among 746 women with a second assessment of PCOS at ages 34-46 years, we estimated the association of persistent PCOS with cardiovascular risk factors. RESULTS: Of 1,127 women, 53 (4.7%) met criteria for PCOS at ages 20-32 years. Polycystic ovary syndrome was associated with a twofold higher odds of incident diabetes (23.1% compared with 13.1%, adjusted odds ratio [AOR] 2.4, confidence interval [CI] 1.2-4.9) and dyslipidemia (41.9% compared with 27.7%, AOR 1.9, CI 1.0-3.6) over the course of 18 years; the association with incident hypertension was not significant (26.9% compared with 26.3%, AOR 1.7, CI 0.8-3.3). Normal-weight women with PCOS (n=31) had a threefold higher odds of incident diabetes compared with normal-weight women without PCOS (AOR 3.1, CI 1.2-8.0). Compared with those without PCOS, women with persistent PCOS (n=11) had the highest odds of diabetes (AOR 7.2, CI 1.1-46.5). CONCLUSION: Polycystic ovary syndrome is associated with subsequent incident diabetes and dyslipidemia, independent of BMI. Diabetes risk may be greatest for women with persistent PCOS symptoms. LEVEL OF EVIDENCE: II.
OBJECTIVE: To estimate whether women aged 20-32 years who fulfilled National Institutes of Health criteria for polycystic ovary syndrome (PCOS) would be at higher risk for subsequent development of incident diabetes, dyslipidemia, and hypertension, and to estimate whether normal-weight women with PCOS would have the same degree of cardiovascular risk as overweight women with PCOS. METHODS: We estimated the association of PCOS with incident diabetes, dyslipidemia, and hypertension over a period of 18 years among 1,127 white and African-American women in the Coronary Artery Risk Development in Young Adults cohort. We classified women at baseline (ages 20-32 years) based on self-reported symptoms and serum androgen measures using National Institutes of Health PCOS criteria. We estimated the association of PCOS and subsequent cardiovascular risk factors, independent of baseline body mass index (BMI), using multivariable logistic regression. Additionally, among 746 women with a second assessment of PCOS at ages 34-46 years, we estimated the association of persistent PCOS with cardiovascular risk factors. RESULTS: Of 1,127 women, 53 (4.7%) met criteria for PCOS at ages 20-32 years. Polycystic ovary syndrome was associated with a twofold higher odds of incident diabetes (23.1% compared with 13.1%, adjusted odds ratio [AOR] 2.4, confidence interval [CI] 1.2-4.9) and dyslipidemia (41.9% compared with 27.7%, AOR 1.9, CI 1.0-3.6) over the course of 18 years; the association with incident hypertension was not significant (26.9% compared with 26.3%, AOR 1.7, CI 0.8-3.3). Normal-weight women with PCOS (n=31) had a threefold higher odds of incident diabetes compared with normal-weight women without PCOS (AOR 3.1, CI 1.2-8.0). Compared with those without PCOS, women with persistent PCOS (n=11) had the highest odds of diabetes (AOR 7.2, CI 1.1-46.5). CONCLUSION:Polycystic ovary syndrome is associated with subsequent incident diabetes and dyslipidemia, independent of BMI. Diabetes risk may be greatest for women with persistent PCOS symptoms. LEVEL OF EVIDENCE: II.
Authors: Anne Corbould; Young-Bum Kim; Jack F Youngren; Celia Pender; Barbara B Kahn; Anna Lee; Andrea Dunaif Journal: Am J Physiol Endocrinol Metab Date: 2004-12-21 Impact factor: 4.310
Authors: Joan C Lo; Seth L Feigenbaum; Jingrong Yang; Alice R Pressman; Joe V Selby; Alan S Go Journal: J Clin Endocrinol Metab Date: 2006-01-24 Impact factor: 5.958
Authors: S Sidney; D R Jacobs; W L Haskell; M A Armstrong; A Dimicco; A Oberman; P J Savage; M L Slattery; B Sternfeld; L Van Horn Journal: Am J Epidemiol Date: 1991-06-15 Impact factor: 4.897
Authors: G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage Journal: J Clin Epidemiol Date: 1988 Impact factor: 6.437
Authors: A R Folsom; G L Burke; C Ballew; D R Jacobs; W L Haskell; R P Donahue; K A Liu; J E Hilner Journal: Am J Epidemiol Date: 1989-11 Impact factor: 4.897
Authors: Kelsey E S Salley; Edmond P Wickham; Kai I Cheang; Paulina A Essah; Nicole W Karjane; John E Nestler Journal: J Clin Endocrinol Metab Date: 2007-12 Impact factor: 5.958
Authors: Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro Journal: Clin Endocrinol (Oxf) Date: 2017-03-09 Impact factor: 3.478
Authors: Margareta D Pisarska; Jessica L Chan; Kate Lawrenson; Tania L Gonzalez; Erica T Wang Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Catherine Kim; Vanita R Aroda; Ronald B Goldberg; Naji Younes; Sharon L Edelstein; MaryLou Carrion-Petersen; David A Ehrmann Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958
Authors: Panagiotis Anagnostis; Rodis D Paparodis; Julia K Bosdou; Christina Bothou; Djuro Macut; Dimitrios G Goulis; Sarantis Livadas Journal: Endocrine Date: 2021-06-26 Impact factor: 3.633
Authors: Melissa F Wellons; Gordon Wright Bates; Pamela J Schreiner; David S Siscovick; Barbara Sternfeld; Cora E Lewis Journal: Menopause Date: 2013-08 Impact factor: 2.953